Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (LIBerate-FH)
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Sponsor: LIB Therapeutics LLC
Listed as NCT04797104, this PHASE3 trial focuses on Heterozygous Familial Hypercholesterolemia and remains completed. Sponsored by LIB Therapeutics LLC, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 3 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Enrolling By Invitation PHASE3
-
May 2021 — Sep 2022 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- LIB Therapeutics LLC
- Medpace, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .